Drugs against lymphoma: a drug against a rare type of blood cancer has been approved in the United States
[ad_1]
The US Food and Drug Administration (FDA) has approved Eli Lilly’s drug for a rare form of blood cancer. It is called Jaypirca, according to the company’s website. The drug has proven effectiveness for patients with relapsed or refractory (refractory) mantle cell lymphoma. It is a rare type of blood cancer that starts in white blood cells in the lymph nodes and spreads aggressively to other parts of the body. Photo: ArturVerkhovetskiy/Depositphotos “The approval of Jaypirca is an important advance for patients with relapsed or refractory MCL who currently have limited options and have historically had a poor prognosis after discontinuation of Bruton covalent tyrosine kinase inhibitor (BTC) treatment,” said University of Texas Cancer Center Professor Michael Wang . The approval of the drug was preceded by clinical studies. Of the 120 patients who were in the early and intermediate stages, 50% responded to the drug and 13% achieved remission. The researchers evaluated the effectiveness of a dose of 200 mg as the maximum permissible amount of the drug per day, but before the appearance of toxicity for other body systems. Patients with mantle cell lymphoma who have completed at least two rounds of chemotherapy are expected to be able to purchase the drug in the coming weeks, Reuters reported. The wholesale cost will be $21,000 per month for a 200 mg dose. The company expects the FDA to approve 4 more drugs within the year, one of which is an anti-obesity drug. Read also: In Britain, a clinic sent cancer news to patients instead of a Christmas greeting
[ad_2]
Original Source Link
